Patents by Inventor Tobias Abel

Tobias Abel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20240067732
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 27, 2023
    Publication date: February 29, 2024
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
    Patent number: 11814432
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: November 14, 2023
    Assignees: The University of British Columbia, Sangamo Therapeutics France
    Inventors: Li Zhou, Tobias Abel, François Meyer, Megan Levings, Nicolas Dawson, Caroline Lamarche
  • CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR INTERLEUKIN-23 RECEPTOR
    Publication number: 20210380704
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) specific for an IL-23 receptor, and to a nucleic acid encoding the same. The present invention further relates to a T cell expressing said CAR, and to the use thereof for treating an autoimmune and/or inflammatory disease or disorder.
    Type: Application
    Filed: April 15, 2019
    Publication date: December 9, 2021
    Applicant: SANGAMO THERAPEUTICS FRANCE
    Inventors: Tobias Abel, Julie Gertner-Dardenne, François Meyer
  • NEW CAR CONSTRUCTS COMPRISING TNFR2 DOMAINS
    Publication number: 20210292389
    Abstract: The present invention relates to a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof, and to an immune cell expressing said CAR. The present invention further relates to therapeutic methods comprising the administration of an immune cell expressing a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof.
    Type: Application
    Filed: August 9, 2019
    Publication date: September 23, 2021
    Applicant: SANGAMO THERAPEUTICS FRANCE
    Inventors: Tobias Abel, David Fenard, Julie Gertner-Dardenne, François Meyer
  • NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
    Publication number: 20200283530
    Abstract: The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.
    Type: Application
    Filed: September 20, 2018
    Publication date: September 10, 2020
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, SANGAMO THERAPEUTICS FRANCE
    Inventors: Li ZHOU, Tobias ABEL, François MEYER, Megan LEVINGS, Nicolas DAWSON, Caroline LAMARCHE
  • ENHANCED TUMOR THERAPY BY TUMOR STEM CELL TARGETED ONCOLYTIC VIRUSES
    Publication number: 20140065694
    Abstract: The invention relates to recombinant oncolytic viruses that target tumor stem cells and various uses of these recombinant viruses. In particular, an oncolytic virus comprising a recombinant binding domain specific for a tumor stem cell marker is disclosed. Furthermore, the use of such oncolytic viruses for the treatment of cancer is disclosed.
    Type: Application
    Filed: March 5, 2012
    Publication date: March 6, 2014
    Applicant: Paul-Ehrlich-Institute of the Federal Republic of Germany
    Inventors: Christian Buchholz, Patricia Bach, Tobias Abel